Aditya Bardia MD

Attending Physician, Massachusetts General Hospital, Harvard Medical School

2336 Santa Monica BlvdSte 304Santa Monica, CA 90404
Phone+1 310-998-4747

Dr. Bardia is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bardia's full profile Already have an account?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2005 - 2008
All India Institute of Medical SciencesClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2024 - 2028
MA State Medical License 2011 - 2025
MD State Medical License 2008 - 2012
MN State Medical License 2007 - 2008
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Start of enrollment: 2012 Aug 07
COMPLETED
PHASE3
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
COMPLETED
PHASE2
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Start of enrollment: 2012 Dec 17
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

1 citations
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Hope S Rugo, Mina S Sedrak, Sibylle Loibl, Sara M Tolaney
JCO Oncology Practice. 2026-05-01
Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.
Maxwell R Lloyd, Caroline M Weipert, Azka Ali, Sheila R Solomon, Jayati Saha
Clinical Cancer Research. 2026-01-06
15 citations
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Peter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, Chiun-Sheng Huang, John Crown
JAMA Oncology. 2025-11-01

Journal Articles

Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances
Aditya Bardia, MD, Clinical Cancer Research
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer
David T Miyamoto, Aditya Bardia, Lecia V Sequist, Laura M Spring, Daniel A Haber, Mark Kalinich, Clinical Cancer Research

Lectures

Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic br...
2019 ASCO Annual Meeting - 6/1/2019
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2âˆ’ advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safe...
2019 ASCO Annual Meeting - 6/1/2019
Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC).
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast CancerJuly 8th, 2025
Challenging Cases in Metastatic Breast CancerMay 15th, 2025
Cancer Drug Dosing Concerns Highlighted by Patient-Led StudyAugust 13th, 2024

Grant Support

Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancerMASSACHUSETTS GENERAL HOSPITAL2022–2026